Company Overview and News

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-09-25 sec.gov
Current Report UNITED STATES
APZ

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-09-12 sec.gov
Current Report UNITED STATES
APZ

 
ASX:APZ / ASPEN GROUP QUARTERLY REPORT (Quarterly Report)

2018-09-10 sec.gov
Quarterly Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION <
APZ

 
Aspen Group Inc. (ASPU) CEO Michael Mathews on Q1 2019 Results - Earnings Call Transcript

2018-09-07 seekingalpha
Good day, ladies and gentlemen. And welcome to the Aspen Group Inc., Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call may be recorded.
MBI APZ ASPU

 
Aspen Group sees losses widen for fiscal first quarter, but beats Wall Street's revenue estimate

2018-09-06 proactiveinvestors.com.au
Aspen Group (NASDAQ:ASPU), the New York-based education technology holding company, fell short of Wall Street's earnings forecast for the fiscal first quarter as its losses mounted, but saw its revenue beat the consensus estimate.
APZ ASPU

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-09-06 sec.gov
Current Report UNITED STATES
APZ

 
Aspen Group Revenue Growth Rate Accelerates to 70% in the First Quarter of Fiscal 2019

2018-09-06 globenewswire
NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq:ASPU), an education technology holding company, today announced financial results for its 2019 fiscal first quarter ended July 31, 2018, highlighted by revenue of $7,221,305, an increase of 70% compared to the first quarter of 2018. This represented an acceleration in revenue growth from 68% growth achieved in the fourth quarter of 2018.
APZ ASPU

 
Aspen Group, Inc. Announces Appointment of Joseph Sevely as Chief Financial Officer

2018-09-06 globenewswire
NEW YORK, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq: ASPU) today announced the appointment of Joseph Sevely as Chief Financial Officer at Aspen Group, Inc. (”AGI”), effective September 11, 2018. Mr. Sevely will oversee the finance, legal, compliance, HR and investor relations functions for AGI. Janet Gill, AGI’s previous CFO, will move to the newly created position of Chief Accounting Officer.
MBI APZ ASPU

 
Aspen Group Inc. 2018 Q4 - Results - Earnings Call Slides

2018-08-31 seekingalpha
The following slide deck was published by Aspen Group Inc. in conjunction with their 2018 Q4 earnings call.
APZ ASPU

16
Aspen Group (ASPU) Q1 Earnings Preview: What to Watch Ahead of the Release

2018-08-30 zacks
Aspen Group (ASPU - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended July 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
APZ FIZZ ASPU

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-08-30 sec.gov
Current Report UNITED STATES
APZ

 
ASX:APZ / ASPEN GROUP AMENDED ANNUAL REPORT (Annual Report)

2018-08-28 sec.gov
10K/A UNITED STATES SECURITIES AND E
APZ

 
Aspen University to Open an Evening/Weekend Program for Pre-Licensure BSN Students

2018-08-27 globenewswire
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (Nasdaq: ASPU) announced today the decision to offer nursing applicants an additional option to study for their pre-licensure BSN degree. Starting in January 2019, an evening/weekend program will be offered to qualified applicants currently sitting on Aspen’s wait list. The pre-licensure BSN curriculum is identical to that offered in the current day program and 69% of student’s coursework will be offered using Aspen’s distance learning modality.
APZ ASPU

 
Aspen Group, Inc. Delivers a Record 1,314 New Student Enrollments in Q1 FY’19

2018-08-20 globenewswire
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Aspen Group, Inc. (“AGI”), (Nasdaq: ASPU), a postsecondary education company, today announced a company record of 1,314 new student enrollments for the fiscal 2019 first quarter, a 52% increase year-over-year. Aspen University accounted for 1,093 new student enrollments (includes 118 Doctoral enrollments and 93 Pre-licensure BSN AZ campus enrollments), while United States University (“USU”) accounted for 221 new student enrollments (primarily Family Nurse Practitioner (“FNP”) enrollments).
APZ ASPU

 
ASX:APZ / ASPEN GROUP CURRENT REPORT (Current Report)

2018-08-01 sec.gov
Current Report UNITED STATES
APZ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...